Page 8 - Iontech News Today

Report of the Supervisory Board on the financial year 2022 The 2022 financial year was a significant and challenging year for BioNTech SE. The Management Board,... | April 13, 2023

English Convenience Translation - the German language joint report is decisive Joint report of the Management Board of BioNTech SE, Mainz, and the management of... | April 13, 2023

Please turn to give instructions. ► Registration and proxy form Ordinary General Meeting of BioNTech SE on 25 May... | April 13, 2023

TEXARKANA, Ark. – The Texarkana Arkansas Board of Directors met on Monday to appoint TyRhonda Henderson, the city’s financial director, to temporarily fill the vacancy of city manager until a

By Will Feuer Arbutus Biopharma Corp. and its licensee Genevant Sciences have filed a patent-infringement lawsuit against Pfizer Inc. and BioNTech SE related to the latters Covid-19 vaccine.... | April 4, 2023

By Will Feuer Arbutus Biopharma Corp. and its licensee Genevant Sciences have filed a patent-infringement lawsuit against Pfizer Inc. and BioNTech SE related to the latters Covid-19 vaccine.... | April 4, 2023

BioNTech receives exclusive licenses from DualityBio for two investigational antibody-drug conjugate assets directed against targets expressed in a broad range of human cancersCollaboration will add... | April 3, 2023

By Chris Wack Biopharmaceutical companies BioNTech SE and Duality Biologics Co. Ltd. have entered into exclusive license and collaboration agreements to develop, manufacture and commercialize... | April 3, 2023

Germanys BioNTech said on Monday that it signed a deal with Chinese biotech company DualityBio to co-develop and commercialize two cancer antibody drug candidates. DualityBio will... | April 3, 2023

BioNTech and Duality Biologics have entered into exclusive license and collaboration agreements for two ADC assets: thus adding ADCs as an additional drug class in BioNTech’s oncology portfolio.